- Home
- PLBY vs CGEN Comparison
PLBY vs CGEN Comparison
Compare PLBY & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLBY | CGEN |
|---|---|---|
| Founded | 1953 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.4M | 191.1M |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PLBY | CGEN |
|---|---|---|
| Price | $1.18 | $2.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 990.7K | 303.0K |
| Earning Date | 05-11-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,928,000.00 | N/A |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $7.10 | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $1.19 | $1.30 |
| 52 Week High | $2.75 | $3.24 |
Technical Indicators
Market Signals| Indicator | PLBY | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 59.80 |
| Support Level | N/A | $1.48 |
| Resistance Level | $1.94 | $3.05 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 2.33 | 97.41 |
Price Performance
Historical ComparisonAbout PLBY PLBY Group Inc.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.